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Large-scale genetic association studies have identified replicable
susceptibility alleles for some psychiatric phenotypes.1 This
includes both common and rare variants. A striking finding has
been that susceptibility variants identified to date often confer
susceptibility to more than one of the traditional clinical pheno-
types, a finding that has the potential to increase understanding
of the biological relationship between these traditional diagnostic
categories.1–3 The focus of this study is childhood attention-deficit
hyperactivity disorder (ADHD) and its potential genetic relationship
to adult schizophrenia and bipolar disorder. There is evidence of
some degree of shared genetic susceptibility between schizophrenia
and childhood ADHD for rare chromosomal variants.4 In the
present study, we have considered another possible source of
genetic overlap, namely common single nucleotide polymorphisms
(SNPs) and we have extended the analysis to consider bipolar
disorder as well as schizophrenia. The only prior study that has
started to examine this, selected six bipolar genetic risk variants
and identified no strong association with ADHD or with scores
on the Mood Disorder Questionnaire.5 Here, we have used a more
powerful, genome-wide approach and examined whether, when
they are considered en masse using polygenic score analysis,6
multiple schizophrenia7 and bipolar disorder8 common risk alleles
contribute to ADHD risk.
Method
In general, we followed the polygenic score analysis approach
described by the International Schizophrenia Consortium
(ISC).6 The basic principle of that analysis was that a set of many
alleles that discriminated case status in a ‘discovery’ schizophrenia
case–control sample, also significantly discriminated case status in
an independent ‘target’ schizophrenia case–control sample. We
used the published Psychiatric Genome-wide Association Study
(GWAS) Consortium (PGC) data-sets (schizophrenia and bipolar




We made use of the PGC schizophrenia7 and bipolar disorder8
case–control data-sets. The schizophrenia sample comprised
9394 cases and 12 462 controls analysed at 1 252 901 SNPs. The
bipolar disorder sample comprised 7481 cases and 9250 controls
analysed at 2 427 089 SNPs. These studies contain individuals of
European origin collected across Europe, the USA, and Australia.
We note that there are a number of control individuals that
contribute to both the PGC schizophrenia and bipolar disorder
samples, including the Wellcome Trust Case Control Consortium
(WTCCC) – Phase 1 control sample.9
Target data
We interrogated genotype data from a UK/Irish ADHD GWAS.10
The sample comprises 727 children aged 4–18 years, recruited
from UK community child psychiatry and paediatric clinics and
from Dublin, Ireland. All children were White, of European origin
and met research diagnostic criteria for DSM-III-R11/DSM-IV12
or ICD-1013 for ADHD or hyperkinetic disorder. Case exclusion
criteria included bipolar disorder, schizophrenia, autism, epilepsy,
intellectual disability (IQ 570) or any known major neurological
or medical disorders. After complete description of the study to
the participants, written informed consent was obtained. The
ADHD GWAS sample also included 5081 UK controls from
WTCCC2.14 Genotyping for the ADHD cases was performed on
the Illumina (San Diego, California, USA, www.illumina.com)
Human 660W-Quad BeadChip, and genotyping for the controls
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Background
There is recent evidence of some degree of shared genetic
susceptibility between adult schizophrenia and childhood
attention-deficit hyperactivity disorder (ADHD) for rare
chromosomal variants.
Aims
To determine whether there is overlap between common
alleles conferring risk of schizophrenia in adults with those
that do so for ADHD in children.
Method
We used recently published Psychiatric Genome-wide
Association Study (GWAS) Consortium (PGC) adult schizophrenia
data to define alleles over-represented in people with
schizophrenia and tested whether those alleles were more
common in 727 children with ADHD than in 2067 controls.
Results
Schizophrenia risk alleles discriminated ADHD cases from
controls (P=1.0461074, R2 = 0.45%); stronger discrimination
was given by alleles that were risk alleles for both adult
schizophrenia and adult bipolar disorder (also derived from a
PGC data-set) (P=9.9861076, R2 = 0.59%).
Conclusions
This increasing evidence for a small, but significant, shared
genetic susceptibility between adult schizophrenia and
childhood ADHD highlights the importance of research work
across traditional diagnostic boundaries.
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was performed using the Illumina Human 1.2M BeadChip. The
samples, quality control assessment and results of the primary
ADHD GWAS are described in detail in a previous paper.10
Statistical analysis
Approximately half of the WTCCC2 control sample had been used
in the primary bipolar disorder GWAS reported by WTCCC19 and
a schizophrenia GWAS reported by our own group,15 both of
which contributed to the PGC studies of bipolar disorder and
schizophrenia respectively. It was, therefore, necessary to remove
those and any overlapping case individuals from our ADHD
GWAS. First, we identified individuals that were included in the
earlier studies (genotyped on Affymetrix GeneChip 500K Mapping
Array; Santa Clara, California, USA, www.affymetrix.com) that
were also present in the primary ADHD GWAS. To do this we
used 71 565 SNPs that were common to the studies that had also
passed our quality control procedures. These SNPs were used to
estimate identity-by-descent statistics for all pair-wise combinations
of individuals. Across the two data-sets, we identified 2474 related
individuals in the control sample, of which 2452 were duplicates,
and no related case individuals. The related controls comprised 13
parent–offspring pairs, 7 sibling pairs, and 2 half-sibling or
avuncular pairs. The duplicates and close relatives were removed
from the control set giving a sample of 2067 control and 727 case
individuals for our analysis of ADHD cases v. controls. Similar
quality control approaches have been applied to our ADHD,10
bipolar disorder9 and schizophrenia15 case and control samples
to exclude overlapping and related individuals. Given that we have
previously provided the results of the full ADHD GWAS
elsewhere,10 we do not provide individual-level SNP results here.
We used PLINK (1.07) for manipulation of the genetic data
and to produce polygenic scores. All statistical analyses were
performed with R (2.11.1). Both PLINK and R were run on Linux
(Fedora release 13, x86_64).
Polygenic analysis
We made comparisons between ADHD cases and controls to
determine whether the schizophrenia and/or bipolar derived
polygenic scores were significantly different. We first selected a
set of SNPs in relative linkage equilibrium in our ADHD and
control sample using a sliding window of 200 SNPs, moving it
along the genome in steps of 5 SNPs and dropping a SNP when
the pair-wise estimate of linkage disequilibrium (r2) was greater
than 0.2 (PLINK command: –indep-pairwise 200 5 0.2).16 From
the results of the GWAS for each PGC sample, we identified for
the selected SNPs their corresponding P-values, associated alleles,
and the odds ratios (OR) for those alleles. Based on the result of
both the ISC6 and PGC studies, our primary analyses are based on
an ‘association’ threshold PT50.5. Alleles that are more common
in the cases for which the two-tailed P-values met the condition
PT50.5 are termed the ‘score’ alleles.
6 For each individual in
the target data, we obtained the polygenic score for that individual
which corresponds to the mean per-SNP product of the number
of score alleles and the loge odds ratios.
6 We employed logistic
regression analysis to compare the polygenic scores in the target
set (ADHD v. controls). As with our ADHD GWAS,10 to allow
for population stratification within the sample, the regression
analysis is performed conditional on two covariates (the first
two principal components estimated from our GWAS data using
EIGENSTRAT17,18 software designed for this purpose). For each
analysis we report the P-value (two-tailed) and pseudo-R2, the
latter being a measure of the estimated variability in case–control
status explained. Analyses were performed separately for score
alleles derived from schizophrenia and bipolar disorder data-sets.
We interrogated the data further by creating polygenic scores
based on simultaneous patterns of association in the PGC
schizophrenia and bipolar disorder data-sets. Specifically, we were
interested in testing the hypothesis that the set of alleles that
showed evidence for association in both schizophrenia and bipolar
disorder was the same set of alleles that was enriched for shared
effects in ADHD risk. Alternative (non-null) hypotheses are that
alleles that were relatively specific for one or the other disorder
were enriched for those that confer risk of ADHD.
To examine these possibilities, we identified six sets of alleles. We
first took the set of alleles at PT50.5 in schizophrenia and divided
them into those that did and those that did not also surpass
PT<0.5 in bipolar disorder. Single nucleotide polymorphisms that
surpassed PT<0.5 in both data-sets were further divided into two
groups dependent on whether the allele that was over-represented
in the bipolar disorder cases (compared with controls) was the
same as the allele over-represented in the schizophrenia cases.
These groups were then analysed separately. We note that, as
expected given shared controls in the PGC schizophrenia and
bipolar disorder GWAS data-sets, and also given the known
overlap in polygenic risk between schizophrenia and bipolar
disorder,6 if an SNP surpassed PT50.5 in schizophrenia, it was
slightly more likely also to do so for bipolar disorder than chance
(Table 1). Moreover, for the same reasons, but most particularly
because of the shared controls, where SNPs surpassed PT50.5
for both schizophrenia and bipolar disorder, for most SNPs, the
same allele was over-represented in both sets of cases compared
with the controls. To help show the relationships between the
six sets of SNPs, a graphical representation of the SNP selection
is provided in the online supplement (online Fig. DS1).
Results
The polygenic score representing schizophrenia risk was significantly
different between ADHD cases and controls, with higher scores
observed in the ADHD cases (Table 1). Attention-deficit hyper-
activity disorder cases also had a higher polygenic score representing
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Table 1 Summary of results in the target sample comparing ADHD cases v. controlsa
ADHD v. controls
Discovery sample SNP selection criteria SNPs, n z-statistic R2,% P
Bipolar disorder Bipolar disorder P50.5 50 512 1.94 0.11 0.0519
Schizophrenia Schizophrenia P50.5 48 494 3.88 0.45 1.0461074
Schizophrenia Schizophrenia P50.5 and bipolar disorder P50.5 22 595 1.63 0.080 0.102
Schizophrenia Schizophrenia P50.5 and bipolar disorder P50.5 25 137 4.40 0.58 1.0961075
Schizophrenia Same direction of effect in schizophrenia and bipolar disorder 17 303 4.42 0.59 9.9861076
Schizophrenia Different direction of effect in schizophrenia and bipolar disorder 7834 1.21 0.044 0.225
ADHD, attention-deficit hyperactivity disorder; SNP, single nucleotide polymorphism.
a. In all analyses, the ADHD cases had more risk alleles than the controls. All z-statistics are distributed with one degree of freedom and all P-values are two-tailed.
Childhood ADHD and adult schizophrenia
bipolar disorder risk but the effect was weaker than that for the
polygenic score representing schizophrenia as estimated by R2, and
just failed to attain a conventional level of statistical significance.
For both analyses, the magnitudes of these effects (as defined by
R2) were much smaller than the 6% or 3% observed when the
discovery and target sets both comprise schizophrenia7 or both
bipolar disorder8 data-sets respectively.
In the analyses based on the patterns of association in schizo-
phrenia conditional on that in bipolar disorder, only the set of
SNPs that surpassed PT50.5 in both samples produced a significant
score difference betweenADHDcases and controls (P=1.0961075).
This effect appeared to be largely driven by the set of alleles with
the same direction of effect in schizophrenia and bipolar disorder
(P= 9.9861076). The scores derived from the set in which the
alleles had opposite effects in schizophrenia than in bipolar
disorder were not significantly different between ADHD cases
and controls. Findings that were significant in Table 1 (plus the
bipolar disorder analysis) are presented in online Fig. DS2 for a
range of different significance thresholds. Consistent with the
findings of the ISC, P<0.5 gives most evidence for discrimination
of ADHD cases from controls. Our significant results are
maintained across the full range of thresholds.
For polygenic score analysis, the number of alleles used in the
analysis can have a large effect on significance and the effect size
estimated from R2. The number of alleles differed substantially
between those that were in the same direction in schizophrenia
and bipolar disorder (n= 17 303) and those that were in opposite
directions (n=7834). We, therefore, undertook a simulation study
to assess the impact of this variable on our evaluation of the
contribution from alleles at SNPs surpassing PT50.5 but for
which the direction of association differed in schizophrenia and
bipolar disorder. From the 25 137 SNPs surpassing PT50.5 in
both disorders (i.e. schizophrenia and bipolar disorder), we
selected at random a subset of 7834 SNPs (i.e. the number that
had been included in the analysis of SNPs showing different
directions of effect), and the remaining subset of 17 303 SNPs
(i.e. the number that had been included in the analysis of SNPs
showing the same direction of effect), and performed polygenic
score analysis on both sets of SNPs. The difference in R2 was
estimated from the two analyses. Repeating the procedure 10 000
times gave a distribution of difference in R2 against which we
could empirically evaluate whether our observation of a weaker
result for the SNPs with opposite directions of effect simply
reflects a smaller set of SNPs being used. In the simulated data,
the probability of observing a difference in R2 at least as large as
that observed in the real data (i.e. observed difference in
R2 = 0.55) was 0.09 (i.e. in 900 out of 10 000 random SNP draws
was a larger difference in R2 detected than in the observed data).
This does not allow us to reject the null hypothesis that there is no
difference in the SNPs associated with schizophrenia and bipolar
disorder at P50.5 with respect to the direction of effect. This
in turn amounts to suggestive evidence (P=0.09) that alleles
that are over-represented in the cases in both schizophrenia and
bipolar disorder GWAS data-sets proportionately capture more
polygenic signal than those alleles that are more common in
schizophrenia, but less common in bipolar disorder, when
compared with controls.
Discussion
Aetiological overlaps between childhood-onset and major adult
psychiatric disorders have, until relatively recently, been ignored
in molecular genetic studies. Here, using a sample of 727 children
and adolescents affected with ADHD and 2607 controls, we have
demonstrated significant evidence for an overlap in polygenic
susceptibility to schizophrenia and ADHD. No significant
evidence was observed for a similar overlap between polygenic
susceptibility to bipolar disorder and ADHD, although the level
of significance was suggestive, so a potential relationship may be
detectable in future studies with larger samples. This is the first
study of its kind to identify a SNP-based relationship between
ADHD risk and that for either schizophrenia or bipolar disorder.
In this study, the overlap between ADHD and schizophrenia
appears stronger than it is between ADHD and bipolar disorder.
However, this could, in part, be related to somewhat lower power
(i.e. smaller sample size) of the PGC bipolar disorder sample than
the PGC schizophrenia samples used in the discovery part of the
analysis, although the differences in sample size are not marked.
The estimated effect sizes of the schizophrenia and bipolar
disorder polygenic risk scores we report here in our ADHD sample
are smaller than those observed by the ISC when taking
schizophrenia-defined score alleles and investigating these in
individuals with schizophrenia or bipolar disorder compared with
controls (2–3% and 1–2% respectively).6 The estimated effect sizes
for bipolar disorder-defined score alleles in our ADHD v. control
analysis are smaller than that observed when we reanalyse our data
using the ISC schizophrenia data-set as discovery data (see the
online supplement). As the ISC sample size (about 7000 individuals
in total) is smaller than that of either the PGC schizophrenia or
bipolar disorder sample, the discovery sample size cannot be a
major factor driving the lower effect sizes seen here.
An observation that may help to provide insight into the
genetic architecture of the relationship between the various
disorders is the larger effect, as measured by R2 for sets of SNPs
that show similar directions of effect in schizophrenia and bipolar
disorder. This observation needs to be treated with some caution
because of the occurrence of some shared controls within the PGC
schizophrenia and bipolar disorder data-sets that biases towards
finding more shared susceptibility alleles than would be expected
under the null hypothesis. Nonetheless, if this observation receives
support in independent studies, it would suggest that not all
schizophrenia susceptibility alleles are equivalent. They may reflect
different phenotypic risk effects. Alternatively, given the overlap in
schizophrenia and bipolar disorder, they may reflect the more
‘replicable’ or true alleles.
It is important to acknowledge that our findings do not
distinguish between susceptibility alleles that may be (a) highly
non-specific and span across multiple psychiatric conditions
(not just schizophrenia and ADHD) and those that may be (b)
relatively specific to schizophrenia and ADHD. Distinguishing
between these possibilities will require studies that include a wider
range of psychiatric phenotypes.
The links between ADHD, other early neurodevelopmental
disorders (notably autism) and later-onset major psychiatric
disorders are of growing interest. A subgroup of children with
ADHD, but not a majority, develops later mood and bipolar
affective disorder. The relationship with schizophrenia has been
less well researched, although it is well recognised that a substantial
proportion of those with schizophrenia and their offspring show
early developmental problems that include attentional difficulties.
Studies of ADHD in families in which a parent is affected with
schizophrenia show that, in comparison with the offspring without
ADHD, the offspring affected with ADHD experienced more
neurological dysfunction,19,20 functional impairment,20 psychotic-
like symptoms21 and an increased risk of developing schizophrenia
spectrum disorders.19,22 A history of DSM-IV childhood ADHD is
also found to be more frequent in patients with schizophrenia
spectrum disorders and in individuals at risk of developing these
disorders than in the general population, although the reported
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prevalence rate of ADHD varies widely, a likely consequence of
sample characteristics.23 Our results suggest that these observed
links may in part follow from a shared genetic liability to ADHD
and schizophrenia and that further investigation of whether they
index specific neurodevelopmental impairments is needed.
Our observation of an overlap in genetic susceptibility for
common variants in the current analysis is consistent with an
observation of an overlap in genetic susceptibility between ADHD
and schizophrenia for rare copy number variants (CNVs).4 In that
study, based on a smaller sample of 366 ADHD case individuals (a
subset of the sample presented here), we found that large
(4500 kb), rare CNVs were significantly more common in cases
than controls,4 and that CNVs identified in the ADHD cases were
significantly enriched for loci previously reported in both autism
(P= 0.0095) and schizophrenia (P=0.010).4 We note that when
excluding ADHD samples known to have large CNVs, our results
are unchanged. Taken together with the current results, this is
supportive evidence for an overlap in common, as well as rare, risk
variants for ADHD and schizophrenia. We propose that in
conjunction with the CNV data, this is suggestive evidence for
the genetic architecture of ADHD being closer to schizophrenia
than bipolar disorder.
As mentioned in the introduction, a striking finding from
GWAS of psychiatric disorders has been the overlap in genetic
association signals across different psychiatric disorders. An
important goal of PGC, the international consortium for
analysing psychiatric GWAS data, is to undertake systematic
cross-disorder analyses using data-sets for schizophrenia, bipolar
disorder, recurrent depression, autism and ADHD.3 The vast
majority of the ADHD data that we report here are not included
within the Cross Disorders Group (CDG) analyses (see online
supplement for details). When the PGC CDG analyses are
available it will be important to explore the similarities and
differences between findings in the two data-sets.
Strengths and limitations
There are several strengths of this study including the systematic
genome-wide approach, the large size of the training samples
and the novelty of the analysis applied to ADHD and
schizophrenia. It is, however, important to consider potential
limitations. As with all large-scale genotyping approaches, there
is the possibility that systematic bias may influence the results.
Population stratification is a confounder that can cause bias in
case–control studies. We do not believe that population
stratification has resulted in the findings presented here. First,
we take into account principal components of our genotype data
to adjust for hidden stratification. Second, the ISC excluded
population stratification as an explanation for the broad effects
seen between cases and controls.6 Finally, it is highly unlikely that
exactly the same stratification differences would occur between the
case and comparison data-sets in both discovery and target
samples.24 We cannot exclude the possibility that genotyping
platform has influenced our results. However, extensive quality
control was performed for the PGC schizophrenia and bipolar
disorder samples,7,8 and the target ADHD GWAS sample10 to
ensure the genotypes for the case and control samples were
comparable. A further potential source of bias is the theoretical
possibility that by chance, or otherwise, our sample could have
unusual phenotypic characteristics that increased the likelihood
of a genetic similarity between ADHD and schizophrenia or
bipolar disorder. Such an eventuality could, in principle, influence
the statistical comparisons and/or limit the generalisability of
findings to other samples. However, although noting that
systematic phenotypic differences could occur, we are not aware
of such selection effects in our sample and have no reason to
believe this affects our results or conclusions.
It is important to stress that the statistical significance seen in
the comparisons we report are driven by large sample sizes, not
large effect sizes. As in previous studies that use the polygenic
score approach,6–8,24–26 the proportion of variance explained is
negligible (51% of the variance in the present study). However,
we should note that the underlying variance being captured
indirectly may be considerably greater. Indeed, in the ISC study,6
although R2 was about 3%, the true total underlying variation in
liability estimated by the polygenic model was approximately 33%,
a conclusion broadly supported by similar analyses of the PGC
data,7,8 and by an analysis of the PGC data using an entirely
different approach.27 As an increasing proportion of the common
genetic variation is accurately captured through increased sample
sizes, it can be expected that much more of the variance
attributable to the polygenic contributions, unique and shared
across disorders, will be explained. This approach may therefore
become an increasingly useful research tool for probing the
relationships between disorders, and even potentially a useful
clinical tool.6
In summary, we provide evidence that common genetic
variation contributes to risk for ADHD. ‘Risk’ alleles from
schizophrenia in particular, and also bipolar disorder to some
extent, are found to differentiate ADHD cases from control
individuals. Our results indicate the need for further studies of
the genetic relationship between ADHD and adult mood and
psychotic disorders.
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